Can I take lazertinib while amivantamab is on hold because of extreme fatigue?

Can You Continue Lazertinib Monotherapy When Amivantamab is Held for Extreme Fatigue?

Yes, you can and should continue lazertinib monotherapy when amivantamab is held for extreme fatigue, as the FDA-approved regimen explicitly allows for independent dose modifications of each agent based on toxicity. 1

Rationale for Continuing Lazertinib

The FDA prescribing information for lazertinib clearly establishes that when used in combination with amivantamab, each drug can be independently modified, interrupted, or discontinued based on individual adverse reactions 1. This is critical because:

• Fatigue is primarily attributable to amivantamab, not lazertinib, in the combination regimen
• Fatigue occurred in 32% of patients receiving amivantamab-lazertinib (with only 3.8% Grade 3-4) 1
• The FDA label specifically states to "continue LAZCLUZE" when amivantamab must be permanently discontinued for certain toxicities 1

Specific Management Algorithm

When extreme fatigue develops:

1. Hold amivantamab immediately while continuing lazertinib 240 mg daily
2. Assess fatigue severity - if Grade 3-4, this warrants the hold
3. Continue lazertinib without interruption unless there are lazertinib-specific toxicities (ILD/pneumonitis, severe rash, or significant hepatotoxicity)
4. Resume amivantamab once fatigue improves to Grade ≤2, potentially with dose reduction or schedule modification
5. If fatigue recurs with amivantamab rechallenge, consider permanent discontinuation of amivantamab while maintaining lazertinib monotherapy

Evidence Supporting Independent Dosing

The MARIPOSA trial data demonstrates that 72% of patients required dose interruptions and 42% required dose reductions 1, indicating that independent management of each agent is standard practice. Importantly:

• 21% permanently discontinued lazertinib for various adverse reactions 1
• The FDA label explicitly addresses scenarios where amivantamab is discontinued but lazertinib continues, particularly for recurrent VTE despite anticoagulation 1

Critical Caveats

Be aware that lazertinib monotherapy is less effective than the combination:

• The MARIPOSA trial included a lazertinib monotherapy arm specifically to assess each component's contribution 2
• While continuing lazertinib maintains some EGFR inhibition, you lose the synergistic benefit of the bispecific antibody targeting EGFR and MET

Monitor closely for:

• ILD/pneumonitis (occurred in 3.1% of combination patients) - requires permanent discontinuation of both agents if confirmed 1
• Dermatologic toxicity (rash in 86%, nail toxicity in 71%) - may require lazertinib dose reduction 1
• Disease progression - may occur sooner without amivantamab

Quality of Life Considerations

Recent literature emphasizes that the amivantamab-lazertinib combination, while highly effective (median PFS 23.7 months, 3-year OS 60%), comes with significantly more toxicity than osimertinib monotherapy 3, 4, 5. Grade ≥3 adverse events occurred in 80% with the combination versus 52% with osimertinib 5.

This makes continuing lazertinib alone during amivantamab holds a reasonable strategy to:

• Maintain EGFR inhibition
• Reduce treatment burden and toxicity
• Preserve quality of life while managing severe fatigue
• Allow potential amivantamab rechallenge once fatigue resolves

The FDA approval structure and dosing guidelines clearly anticipate and permit this exact clinical scenario 1.